Distributor inventory
Dapagliflozin 5 mg + Metformin 1000 mg (as Metformin Hydrochloride)
Treatment of type 2 diabetes mellitus in adults to improve glycaemic control (as an adjunct to diet and exercise), especially when control is inadequate with metformin or when combination therapy is appropriate.
Dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, increasing urinary glucose excretion and lowering blood sugar. Metformin decreases hepatic glucose production and improves insulin sensitivity, reducing glucose absorption and improving peripheral glucose uptake.
Oral tablet. Take exactly as prescribed, usually once or twice daily with meals to reduce stomach upset (metformin component). Swallow whole with water; do not crush/chew. Maintain adequate hydration; follow diet/exercise advice and monitor blood glucose as directed.
Common side effects of GLEDEPA MET 5/1000MG may include:
Type 2 diabetes only (not for type 1 diabetes). Risk of lactic acidosis with metformin (higher risk in kidney impairment, dehydration, severe infection, hypoxia, excessive alcohol); stop and seek urgent care if rapid breathing, severe weakness, abdominal pain, or drowsiness occur. Dapagliflozin can cause genital mycotic infections, UTIs, volume depletion/low BP, and rarely diabetic ketoacidosis (may occur even with near-normal glucose); seek care for nausea/vomiting, abdominal pain, breathlessness. Assess kidney function before and during treatment; avoid/use with caution in renal impairment as per clinician. Temporarily withhold during major surgery, acute illness, prolonged fasting, or before iodinated contrast procedures per doctor advice. Monitor for hypoglycaemia if used with insulin/sulfonylureas.
